A business in context

ERNA research notebook

Read the disclosures. Follow the relationships. Keep the dates in view.

Research JSON

Filing timeline

Download filings CSV

SEC submissions · retrieved 2026-10-23 · 8022 issuers; up to 32 recent company reports and 8 ownership-change filings per issuer

  1. 8-K · Current report

    Report date 2026-10-15 · 0001493152-26-047287 · Items 7.01,9.01

  2. 8-K · Current report

    Report date 2026-09-16 · 0001493152-26-042963 · Items 7.01,9.01

  3. 8-K · Current report

    Report date 2026-09-14 · 0001493152-26-042934 · Items 5.02

  4. 4 · Ownership change

    Report date 2026-08-31 · 0001493152-26-041137

  5. 4 · Ownership change

    Report date 2026-08-31 · 0001493152-26-041135

  6. 4 · Ownership change

    Report date 2026-08-31 · 0001493152-26-041133

  7. 4 · Ownership change

    Report date 2026-08-31 · 0001493152-26-041132

  8. 4 · Ownership change

    Report date 2026-08-31 · 0001493152-26-041131

  9. 4 · Ownership change

    Report date 2026-08-31 · 0001493152-26-041130

  10. 10-Q · Quarterly report

    Report date 2026-06-30 · 0001493152-26-036424

  11. 8-K · Current report

    Report date 2026-07-02 · 0001493152-26-031930 · Items 7.01,9.01

  12. 8-K · Current report

    Report date 2026-07-01 · 0001493152-26-031920 · Items 5.07,9.01

  13. 8-K · Current report

    Report date 2026-06-22 · 0001493152-26-030306 · Items 5.02,9.01

  14. DEF 14A · Proxy statement

    Report date 2026-05-11 · 0001493152-26-022281

  15. 10-Q · Quarterly report

    Report date 2026-03-31 · 0001493152-26-022276

  16. 8-K · Current report

    Report date 2026-05-01 · 0001493152-26-021112 · Items 5.03,9.01

  17. 8-K · Current report

    Report date 2026-03-18 · 0001493152-26-011922 · Items 3.01

  18. 10-K · Annual report

    Report date 2025-12-31 · 0001493152-26-010102

  19. 8-K · Current report

    Report date 2026-02-26 · 0001493152-26-008182 · Items 7.01,9.01

  20. 4 · Ownership change

    Report date 2026-02-10 · 0001104659-26-016680

  21. 8-K · Current report

    Report date 2026-02-06 · 0001493152-26-006227 · Items 1.01,8.01,9.01

  22. 8-K · Current report

    Report date 2025-12-11 · 0001493152-25-027167 · Items 7.01,9.01

  23. 10-Q · Quarterly report

    Report date 2025-09-30 · 0001493152-25-021287

  24. 10-Q · Quarterly report

    Report date 2025-06-30 · 0001493152-25-011910

  25. 4 · Ownership change

    Report date 2025-06-21 · 0001641172-25-018063

  26. 8-K · Current report

    Report date 2025-06-30 · 0001641172-25-018009 · Items 4.01,9.01

  27. 8-K · Current report

    Report date 2025-06-12 · 0001641172-25-014877 · Items 5.03,9.01

  28. 8-K · Current report

    Report date 2025-06-09 · 0001641172-25-014318 · Items 3.02,8.01

  29. 8-K · Current report

    Report date 2025-06-02 · 0001641172-25-013249 · Items 5.03,5.07,9.01

  30. 10-Q · Quarterly report

    Report date 2025-03-31 · 0001641172-25-009044

  31. DEF 14A · Proxy statement

    Report date 2024-12-31 · 0001641172-25-004585

  32. 8-K · Current report

    Report date 2025-03-31 · 0001641172-25-002514 · Items 1.01,3.02,5.08,9.01

  33. 8-K · Current report

    Report date 2025-03-26 · 0001641172-25-000681 · Items 5.03,9.01

  34. 8-K · Current report

    Report date 2025-03-20 · 0001641172-25-000300 · Items 1.01,2.03,9.01

  35. 10-K · Annual report

    Report date 2024-12-31 · 0001493152-25-010051

  36. 8-K · Current report

    Report date 2025-03-11 · 0001493152-25-010049 · Items 1.01,2.03,9.01

  37. 8-K · Current report

    Report date 2025-02-07 · 0001493152-25-006446 · Items 5.08

  38. 8-K · Current report

    Report date 2025-01-03 · 0001493152-25-001704 · Items 3.01,5.02

  39. 8-K · Current report

    Report date 2024-12-30 · 0001493152-25-000246 · Items 3.01

  40. 10-Q · Quarterly report

    Report date 2024-09-30 · 0001493152-24-044841

Reported insider transactions

Download transactions CSV

SEC insider transactions · retrieved 2026-10-23 · 2026 Q3: filings in this completed quarter; not a live transaction feed

Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.

Transaction rows by code · counts, not monetary totals
Purchase: 0 transaction rows0PSale: 0 transaction rows0SGrant / award: 8 transaction rows8AExercise / conversion: 0 transaction rows0MTax / exercise payment: 0 transaction rows0FGift: 0 transaction rows0G
P · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift

8 matching transaction rows.

Transaction / filedReporting ownerTypeSecuritySharesReported price
2026-08-31
2026-09-01
Bristol James ArthurA · Grant / award
Acquired
Stock Option (Right to buy)
Derivative security
8320.00.0
2026-08-31
2026-09-01
Bristol James ArthurA · Grant / award
Acquired
Stock Option (Right to buy)
Derivative security
5083.00.0
2026-08-31
2026-09-01
Cicala PeterA · Grant / award
Acquired
Stock Option (Right to buy)
Derivative security
5083.00.0
2026-08-31
2026-09-01
Cicala PeterA · Grant / award
Acquired
Stock Option (Right to buy)
Derivative security
5943.00.0
2026-08-31
2026-09-01
Polinsky DavidA · Grant / award
Acquired
Stock Option (Right to buy)
Derivative security
5083.00.0
2026-08-31
2026-09-01
Wexler William A.A · Grant / award
Acquired
Stock Option (Right to buy)
Derivative security
5943.00.0
2026-08-31
2026-09-01
Ratner ElenaA · Grant / award
Acquired
Stock Option (Right to buy)
Derivative security
5944.00.0
2026-08-31
2026-09-01
Luther SanjeevA · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
118848.00.0

Identity & relationships

Wikidata structured data · retrieved 2026-10-23 · 1658 unambiguous CIK-linked entities; coverage is incomplete

These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.

SEC issuer · 0000748592Ernexa Therapeutics Inc.

No parent relationship is available in this import; this is not proof of independence.

No verified LEI join available.

GLEIF legal entity reference data · retrieved 2026-10-23 · 1197 checked identities; 0 unavailable records

Search names and former names
  • Eterna Therapeutics Inc. · former SEC name · 2022-10-24 to 2025-04-04
  • Brooklyn ImmunoTherapeutics, Inc. · former SEC name · 2021-03-26 to 2022-10-14
  • NTN BUZZTIME INC · former SEC name · 2005-09-01 to 2021-03-23
  • NTN COMMUNICATIONS INC · former SEC name · 1994-02-14 to 2005-12-20

Revenue in constant purchasing power

USD revenue expressed in 2026-09 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.

Year endedReported USD revenueCPI-adjusted USD revenue
2024-12-31$582.0K$625.1K
2023-12-31$68.0K$75.2K
2022-12-31$0$0
2020-12-31$5.80M$7.55M
2019-12-31$19.81M$26.10M
2018-12-31$23.34M$31.31M
2017-12-31$21.27M$29.24M

Bureau of Labor Statistics · retrieved 2026-10-23 · 9 selected series; gaps remain missing

Explore the CPI history ↗